HER2-positive metastatic, parotid salivary duct carcinoma treated with a trastuzumab/pertuzumab-based chemotherapy: A case report.

Date publication

décembre 2020

Journal

Clinical case reports

Auteurs

Membres identifiés du Cancéropôle Est :
Dr LONGO Raffaele

Tous les auteurs :
Longo R, Legros PO, Talbi M, Wagner M, Paraschiv EA, Campitiello M, Plastino F, Rozzi A

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/33363842

Résumé

This case highlights the rare entity, salivary duct carcinoma (SDC), which is difficult to diagnose and manage. It is the first published case of a metastatic, HER2-positive parotid SDC successfully treated by a dual anti-HER2 treatment associated to a chemotherapy.

Mots clés

HER2, duct carcinoma, parotid, pertuzumab, trastuzumab

Référence

Clin Case Rep. 2020 Dec;8(12):2878-2882